Found: 15
Select item for more details and to access through your institution.
Innovative methods for rare disease drug development.
- Published in:
- Journal of the Royal Statistical Society: Series A (Statistics in Society), 2022, v. 185, p. S757, doi. 10.1111/rssa.12828
- By:
- Publication type:
- Article
Association between life-course socioeconomic position and inflammatory biomarkers in older age: a nationally representative cohort study in Taiwan.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Admission rates and in-hospital mortality for hip fractures in England 1998 to 2009: time trends study.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Admission rates and in-hospital mortality for hip fractures in England 1998 to 2009: time trends study.
- Published in:
- Journal of Public Health, 2011, v. 33, n. 2, p. 284
- By:
- Publication type:
- Article
Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001.
- Published in:
- Cancers, 2024, v. 16, n. 1, p. 140, doi. 10.3390/cancers16010140
- By:
- Publication type:
- Article
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2.
- Published in:
- Liver International, 2020, v. 40, n. 8, p. 2008, doi. 10.1111/liv.14462
- By:
- Publication type:
- Article
Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 1, p. 53, doi. 10.1007/s40261-020-00979-3
- By:
- Publication type:
- Article
The performance of automated case-mix adjustment regression model building methods in a health outcome prediction setting.
- Published in:
- Health Care Management Science, 2011, v. 14, n. 3, p. 267, doi. 10.1007/s10729-011-9159-6
- By:
- Publication type:
- Article
Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 1, p. 77, doi. 10.1002/cpt.2919
- By:
- Publication type:
- Article
Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 2261, doi. 10.2147/CMAR.S193739
- By:
- Publication type:
- Article
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 4, p. 505, doi. 10.1007/s11523-023-00975-5
- By:
- Publication type:
- Article
Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 371, doi. 10.1093/oncolo/oyab030
- By:
- Publication type:
- Article
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 1, p. 13, doi. 10.1002/onco.13977
- By:
- Publication type:
- Article
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 1, p. 22, doi. 10.1002/onco.13976
- By:
- Publication type:
- Article